Comedian Nikki Glaser, host of the 2025 Golden Globe Awards ceremony, dove right in at the start of her opening monologue: ...

Investor interest in companies with obesity candidates in their pipeline clearly remains high, given that a brand new ...

Verdiva launches with an oversubscribed Series A financing of $411M, co-led by Forbion and General Atlantic, with additional participation from RA Capital Management, OrbiMed, Logos Capital ... and ...

The list extends into the pharma industry, including Pfizer, GSK, and Novo Nordisk. On 14 November, Eli Lilly became a part of this group, after an account using its name and logo sent out a Tweet ...

Financing was co-led by Forbion and General Atlantic, with participants such as RA Capital Management, OrbiMed, and Lilly Asia Ventures.

Ozempic, Wegovy and Mounjaro featured prominently. Known for their use in managing type 2 diabetes and aiding weight loss for ...

But Novo Nordisk's semaglutide drugs have stronger brand recognition in the market because both drugs (Ozempic for diabetes, and Wegovy for obesity) entered earlier and have better well-known.

Guggenheim raised the firm’s price target on Novo Nordisk (NVO) to DKK 798 from DKK 795 and keeps a Buy rating on the shares. The firm is ...

UBS analyst Jo Walton maintained a Buy rating on Novo Nordisk (0QIU – Research Report) today and set a price target of DKK750.00. The company’s shares closed last Friday at DKK637.20.

We recently published a list of These 10 Firms Took A Hit on Friday. In this article, we are going to take a look at where ...

With nearly $14 billion in sales in 2023, it shows no signs of slowing down, much to the delight of its Danish manufacturer, Novo Nordisk A/S (NYSE: NVO). A Scandinavian economic behemoth ...